Rapt Therapeutics $RAPT Stock Position Reduced by AJU IB Investment Co. Ltd.

Key Points

• AJU IB Investment Co. Ltd. significantly reduced its stake in Rapt Therapeutics by 87.5%, now holding only 12,437 shares, representing about 0.1% of its portfolio.
• Several institutional investors increased their positions in Rapt, with Nuveen Asset Management boosting its stake by 50.5% and Invesco Ltd. raising its position by 411.7% during the first quarter.
• Rapt Therapeutics' stock is currently trading at $18.00 with a market capitalization of approximately $297.72 million, while analysts have a consensus price target of $21.57.

AJU IB Investment Co. Ltd. trimmed its holdings in shares of Rapt Therapeutics (NASDAQ:RAPT - Free Report) by 87.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,437 shares of the company's stock after selling 87,066 shares during the period. Rapt Therapeutics comprises approximately 0.1% of AJU IB Investment Co. Ltd.'s portfolio, making the stock its 8th largest position. AJU IB Investment Co. Ltd. owned about 0.08% of Rapt Therapeutics worth $99,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Simplicity Wealth LLC purchased a new stake in Rapt Therapeutics during the first quarter valued at about $25,000. Invesco Ltd. boosted its position in Rapt Therapeutics by 411.7% during the first quarter. Invesco Ltd. now owns 58,901 shares of the company's stock valued at $72,000 after buying an additional 47,391 shares during the period. Comerica Bank boosted its position in Rapt Therapeutics by 53.9% during the first quarter. Comerica Bank now owns 89,327 shares of the company's stock valued at $109,000 after buying an additional 31,287 shares during the period. Callan Family Office LLC boosted its position in Rapt Therapeutics by 53.9% during the first quarter. Callan Family Office LLC now owns 89,327 shares of the company's stock valued at $109,000 after buying an additional 31,287 shares during the period. Finally, Checkpoint Capital L.P. purchased a new stake in Rapt Therapeutics during the first quarter valued at about $134,000. 99.09% of the stock is currently owned by hedge funds and other institutional investors.

Rapt Therapeutics Stock Performance

Shares of RAPT stock traded up $0.80 during mid-day trading on Monday, reaching $20.66. 108,449 shares of the company's stock traded hands, compared to its average volume of 115,049. Rapt Therapeutics has a 12 month low of $5.67 and a 12 month high of $26.56. The firm has a 50 day moving average price of $12.31 and a two-hundred day moving average price of $9.58. The firm has a market capitalization of $341.59 million, a PE ratio of -1.45 and a beta of -0.10.

Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.04). As a group, equities analysts expect that Rapt Therapeutics will post -2.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently issued reports on RAPT. JPMorgan Chase & Co. raised Rapt Therapeutics from an "underweight" rating to a "neutral" rating and set a $14.00 target price on the stock in a research note on Wednesday, July 30th. HC Wainwright raised their target price on Rapt Therapeutics to $27.00 and gave the stock a "buy" rating in a research note on Thursday, July 10th. Zacks Research cut Rapt Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, August 22nd. Wells Fargo & Company reissued an "overweight" rating and issued a $38.00 target price (down from $51.00) on shares of Rapt Therapeutics in a research note on Friday, August 8th. Finally, Wall Street Zen upgraded shares of Rapt Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, September 13th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $21.57.

Rapt Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.